Enter your keyword



The following select publications are from the peer-reviewed literature and discuss the scientific data surrounding the use of OXi4503.

OXi4503 (Combretastatin A1-Phosphate/CA1P)

Clinical—Phase 1 Studies:

Bosse RC, Wasserstrom B, Wise E, Meacham A, Cogle CR. Chemosensitizing leukemia by targeting the leukemia microenvironment with vascular disrupting combretastatins [abstract]. Blood. 2014;124(21):2315.

Cummings J, Zweifel M, Smith N, Ross P, Peters J, Rustin G, et al. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trialBr J Cancer. 2012;106(11):1766-1771.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012;18(5):1415-1425.

Turner D, Gonzalez A, Pettiford L, Meacham A, Wise E, Bosse RC, et al. A phase I study of the vascular disrupting combretastatin, OXi4503, in patients with relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [abstract]. Blood. 2013;122(21):1463.


Benezra M, Phillips E, Tilki D, Ding BS, Butler J, Dobrenkov K, et al. Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent. Leukemia. 2012;26(8):1771-1778.

Bosse RC, Wasserstrom B, Meacham A, Wise E, Drusbosky L, Walter GA, et al. Chemosensitizing AML cells by targeting bone marrow endothelial cells. Exp Hematol. 2016;44(5):363-377.

Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 2002;22(3):1453-1458.

Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003;23(2B):1433-1440.

Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 2010;116(9):1539-1547.

Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008;28(4B):2027-2031.

Siim B, Walicke P, Chaplin D. Activity of the vascular disrupting agent Oxi4503 against an acute myelogenous leukemia xenograft model [abstract]. Cancer Res. 2009;69:5640.